Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Exercise Test × 30 days × Clear all

Sponsor

Conditions

Lung Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Obesity 1 Lymphoma, Non-Hodgkin 1 Inflammatory Breast Neoplasms 1 Hodgkin Disease 1 Hematopoietic and Lymphatic System Neoplasm 1 Heart Defects, Congenital 1 Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 1 Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡